BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM. Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile. The American Journal of Cardiology 2006;98:46-52. [DOI: 10.1016/j.amjcard.2006.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opinion on Pharmacotherapy 2006;7:2533-46. [DOI: 10.1517/14656566.7.18.2533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Sica DA. ?-Blockers in Hypertension: A Reassessment of the Benefit of Combined ?-/?-Blockade. J Clin Hypertension 2007;9:4-9. [DOI: 10.1111/j.1524-6175.2007.06623.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Frishman WH, Henderson LS, Lukas MA. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Vasc Health Risk Manag 2008;4:1387-400. [PMID: 19337551 DOI: 10.2147/vhrm.s3148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Abraham WT. Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure. Congest Heart Fail 2008;14:272-80. [PMID: 18983291 DOI: 10.1111/j.1751-7133.2008.00013.x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis 2009;52:153-67. [PMID: 19732607 DOI: 10.1016/j.pcad.2009.05.002] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
6 Fonarow GC, Deedwania P, Fonseca V, Nesto RW, Watson K, Tarka E, Lukas MA, Madan A, Shabbout M. Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. J Am Soc Hypertens 2009;3:210-20. [PMID: 20409961 DOI: 10.1016/j.jash.2009.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
7 Miller AB, Reichek N, St. John Sutton M, Iyengar M, Henderson LS, Tarka EA, Bakris GL. Importance of blood pressure control in left ventricular mass regression. Journal of the American Society of Hypertension 2010;4:302-10. [DOI: 10.1016/j.jash.2010.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
8 Fonarow GC. Role of carvedilol controlled-release in cardiovascular disease. Expert Review of Cardiovascular Therapy 2014;7:483-98. [DOI: 10.1586/erc.09.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]